Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease

Östlund, Isak; Werner, Mårten; Karling, Pontus

doi:10.1080/00365521.2020.1854342

Cited by 16 publications

(13 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBD-Home 29% of patients were compliant to the IBD-Home application and FC test kit after one year. Patients who were compliant experienced a rise in medical treatment, providing the value to remote disease monitoring [83].…”

Section: Healthpromisementioning

confidence: 99%

“…Similarly, the DH intervention IBD-Home was tested for its feasibility in clinical practice. IBD-Home consists of a mobile application and home-based FC test kit to help patients monitor their disease by reporting symptoms and receive assessments of their intestinal inflammation [83]. The randomized controlled trial measured patient satisfaction and adherence to the application; however a low compliance rate of 29% among the 84 IBD patients who received IBD-Home paired with standard care was reported.…”

Section: Dh In Monitoringmentioning

confidence: 99%

“…In addition, after controlling for age, gender, and FC, the intervention group had higher medical treatment than the control. An increase in treatment was associated with compliance, suggesting that monitoring of compilers' disease activity was effective [83].…”

Section: Dh In Monitoringmentioning

confidence: 99%

“…For instance, the IBD-Home application and remote FC test kit had a low compliance rate, which investigators attributed to users being in long-term remission. This can be justified by the notion that patients in remission may not be motivated to use DH tools because their disease activity has been managed well [83]. Adherence to other DH services such as IBDoc was also low due to users not being suited to remote monitoring and problems with the functionality of the app.…”

Section: Summary Of Evidencementioning

confidence: 99%

See 3 more Smart Citations

Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review

Majidova¹,

Handfield²,

Kafi³

et al. 2021

Genes

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), subdivided into Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases that are characterized by relapsing and remitting periods of inflammation in the gastrointestinal tract. In recent years, the amount of research surrounding digital health (DH) and artificial intelligence (AI) has increased. The purpose of this scoping review is to explore this growing field of research to summarize the role of DH and AI in the diagnosis, treatment, monitoring and prognosis of IBD. A review of 21 articles revealed the impact of both AI algorithms and DH technologies; AI algorithms can improve diagnostic accuracy, assess disease activity, and predict treatment response based on data modalities such as endoscopic imaging and genetic data. In terms of DH, patients utilizing DH platforms experienced improvements in quality of life, disease literacy, treatment adherence, and medication management. In addition, DH methods can reduce the need for in-person appointments, decreasing the use of healthcare resources without compromising the standard of care. These articles demonstrate preliminary evidence of the potential of DH and AI for improving the management of IBD. However, the majority of these studies were performed in a regulated clinical environment. Therefore, further validation of these results in a real-world environment is required to assess the efficacy of these methods in the general IBD population.

show abstract

Section: Healthpromisementioning

confidence: 99%

Section: Dh In Monitoringmentioning

confidence: 99%

Section: Dh In Monitoringmentioning

confidence: 99%

Section: Summary Of Evidencementioning

confidence: 99%

See 2 more Smart Citations

Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review

Majidova¹,

Handfield²,

Kafi³

et al. 2021

Genes

View full text Add to dashboard Cite

show abstract

“…Studies exploring barriers to surveillance by fecal tests have found that blood testing is preferred to fecal testing and suggest that only patients with active disease are likely to comply with a stool test 20 , 25 . Surveillance studies carried out when patients are stable consistently found adherence of only 30% for completing four or more repeated fecal tests 21 , 22 , 26 . Survey studies have revealed that a major reason for poor compliance on repeated fecal screening was avoidance/forgetfulness 27 , 28 and over 60% of respondents stated that the reason for low acceptability of fecal tests was disgust/embarrassment in stool collection 23 , 25 , 29 .…”

Section: Introductionmentioning

confidence: 99%

A hands-free stool sampling system for monitoring intestinal health and disease

Grego

Welling

Miller

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Analysis of stool offers simple, non-invasive monitoring for many gastrointestinal (GI) diseases and access to the gut microbiome, however adherence to stool sampling protocols remains a major challenge because of the prevalent dislike of handling one’s feces. We present a technology that enables individual stool specimen collection from toilet wastewater for fecal protein and molecular assay. Human stool specimens and a benchtop test platform integrated with a commercial toilet were used to demonstrate reliable specimen collection over a wide range of stool consistencies by solid/liquid separation followed by spray-erosion. The obtained fecal suspensions were used to perform occult blood tests for GI cancer screening and for microbiome 16S rRNA analysis. Using occult blood home test kits, we found overall 90% agreement with standard sampling, 96% sensitivity and 86% specificity. Microbiome analysis revealed no significant difference in within-sample species diversity compared to standard sampling and specimen cross-contamination was below the detection limit of the assay. Furthermore, we report on the use of an analogue turbidity sensor to assess in real time loose stools for tracking of diarrhea. Implementation of this technology in residential settings will improve the quality of GI healthcare by facilitating increased adherence to routine stool monitoring.

show abstract